Skip to main content
Fig. 1 | Cancer Nanotechnology

Fig. 1

From: Retro-inversion follicle-stimulating hormone peptide-modified nanoparticles for delivery of PDK2 shRNA against chemoresistant ovarian cancer by switching glycolysis to oxidative phosphorylation

Fig. 1

Expression of PDK2 in ovarian cancer tissues and cell lines. A Expression of PDK2 in ovarian cancer and normal tissues of the GEO database (GSE26712). **P < 0.01. B Kaplan–Meier survival curve delineating PFS between the low and high PDK2 expression groups from the GEO database (GSE26712). C Representative images of immunohistochemical staining for PDK2 in ovarian cancer tissues (200X). 1–2, chemosensitive ovarian cancer tissues. 3–4, chemoresistant ovarian cancer tissues. D Expression of PDK2 protein in A2780, A2780cp, Caov3, HEY, SKOV3 and ES2 ovarian cancer cell lines via Western blot

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us